Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
The bulk of the IPOs proceeds will help bankroll the companys planned Phase III trial for its lead obesity candidate MET-097i, an injectable, ultra-long-acting GLP-1 receptor agonist that is currently in Phase II trials
has received lecture fees from AstraZeneca and Novo Nordisk
Many people unknowingly reduce their medication effectiveness through everyday handling mistakes
Neoadjuvant Setting: Specifically, caution is advised for patients using GLP-1 RAs during neoadjuvant regimens like the phase 3 KEYNOTE-522 trial (NCT03036488)
This information helps you plan financially
It typically involves your provider submitting clinical documentation showing that you meet the medical criteria for treatment, such as your BMI, weight-related health conditions, and previous weight loss attempts
US$ 28.12
US$ 29.34
US$ 21.44
US$ 24.22
